Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | TARDBP | Q13148 | 2/20 | 0.74 |
| ▸ | ACHE | P22303 | 4/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.60 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12478414 | 1.00 | KMT2A (0.74) | KMT2ATARDBPACHEHSD17B10CYP2C9 | |
| SCHEMBL15123829 | 0.88 | KMT2A (0.65) | KMT2ATARDBPACHEHSD17B10CYP2C9 | |
| SCHEMBL15123831 | 0.88 | KMT2A (0.65) | KMT2ATARDBPACHEHSD17B10CYP2C9 | |
| SCHEMBL7844379 | 0.87 | HSD17B10 (0.71) | KMT2ATARDBPACHEHSD17B10CYP2C9 | |
| SCHEMBL17265767 | 0.87 | HSD17B10 (0.71) | KMT2ATARDBPACHEHSD17B10CYP2C9 | |
| SCHEMBL22389375 | 0.86 | ACHE (0.66) | KMT2ATARDBPACHEHSD17B10CYP2C9 | |
| Thioctic Acid Amide SCHEMBL4380181 | 0.86 | KMT2A (1.00) | KMT2ATARDBPACHEHSD17B10CYP2C9 | |
| Thioctic Acid Amide SCHEMBL41833 | 0.86 | KMT2A (1.00) | KMT2ATARDBPACHEHSD17B10CYP2C9 | |
| Thioctic Acid Amide SCHEMBL50599 | 0.86 | KMT2A (1.00) | KMT2ATARDBPACHEHSD17B10CYP2C9 | |
| Thioctic Acid Amide SCHEMBL13093778 | 0.86 | KMT2A (1.00) | KMT2ATARDBPACHEHSD17B10CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127242-A1 | N-LIPOIC-AMINO ACID OR PEPTIDE, DERIVATIVES AND THEIR USES | NEOSTRATA COMPANY INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-11155531-B2 | N-lipoic-amino acid or peptide, derivatives and their uses | NEOSTRATA COMPANY, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20190161467-A1 | N-LIPOIC-AMINO ACID OR PEPTIDE, DERIVATIVES AND THEIR USES | NEOSTRATA COMPANY, INC. | 2019-05-30 | — | — | US | disclosed |
| US-20140315786-A1 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20130190327-A1 | BIS-FATTY ACID CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2012115695-A1 | BIS-FATTY ACID CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | disclosed |
| US-6313164-B1 | TO ENHANCE THE ACTIVITY OF GLUTATHIONE RECLUCTASE; FOR THERAPY AND PROPHYLAXIS OF CARTARACTS | SANKYO COMPANY, LIMITED (JP) | 2001-11-06 | — | — | US | disclosed |
| EP-1070710-A2 | Dithiolan derivatives, their preparation and their therapeutic effect | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
| US-6013663-A | CATARACT THERAPY OR PREVENTION | SANKYO COMPANY, LIMITED (JP) | 2000-01-11 | — | — | US | disclosed |
| EP-0869126-A1 | Dithiolan derivatives, their preparation and their therapeutic effect | Sankyo Company Limited (JP) | 1998-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155531-B2 | N-lipoic-amino acid or peptide, derivatives and their uses | CUTA, ALAD, NGLY1 | KMT2A 4032/4885TARDBP 3172/4885ACHE 2805/4885 |
| US-20140315786-A1 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | GAA, GUSB, ACER2 | KMT2A 4512/4885TARDBP 3181/4885ACHE 229/4885 |
| US-20130190327-A1 | BIS-FATTY ACID CONJUGATES AND THEIR USES | FASN, ELOVL1, ELOVL5 | KMT2A 1577/4885TARDBP 725/4885ACHE 1947/4885 |
| US-20190161467-A1 | N-LIPOIC-AMINO ACID OR PEPTIDE, DERIVATIVES AND THEIR USES | CUTA, ALAD, NGLY1 | KMT2A 4032/4885TARDBP 3172/4885ACHE 2805/4885 |
| US-20220127242-A1 | N-LIPOIC-AMINO ACID OR PEPTIDE, DERIVATIVES AND THEIR USES | CUTA, ALAD, NACA | KMT2A 4073/4885TARDBP 1583/4885ACHE 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.